The pharmaceutical industry is experiencing a significant transformation, necessitating Contract Research Organizations (CROs) to adapt and evolve to remain competitive and effective partners. This report highlights the emerging trends and challenges in the pharma sector and outlines how Future-Fit CROs can capitalize on these changes.
What you'll learn:
- The impact of rising costs to bring a new drug to market
- The key levers for cost reduction
- What's shifting in the pharma landscape and industry trends
- The importance of strategic partnerships with Small and midsize pharma companies (SMIDs)
Data is a unique asset with the power to transform your business. By adopting strategic data monetization practices, life sciences companies can unlock new value and drive sustainable growth.
Future-Fit CROs must embrace these trends and adapt their strategies to support the evolving needs of the pharma industry. Read our report to learn how they can improve efficiency, foster stronger partnerships, and drive significant advancements in drug development.
Download the Report
ALVAREZ & MARSAL BOLSTERS ITS HEALTHCARE PRACTICE IN SOUTHEAST ASIA (ASEAN) REGION WITH THE APPOINTMENT OF SANATH KUMAR AS MANAGING DIRECTOR
September 1, 2025
Leading global professional services firm Alvarez & Marsal (A&M) has announced the appointment of Sanath Kumar as Managing Director within its Southeast Asia and Australia (SEAA) business unit. Based in Singapore, Mr. Sanath will play a strategic role in building out A&M’s Healthcare and Life Sciences practice across ASEAN markets.
Next-Generation Antibodies: A New Era in Immuno-Oncology
August 25, 2025
As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.
Strategic Patience in GenAI - A smarter path to AI leadership
August 11, 2025
As Generative AI accelerates across industries, life sciences firms must seek to adopt strategic patience, prioritizing long-term enterprise value over generating short-term media headlines.
The U.S. Pharma Premium: Who’s Really Paying the Price?
June 30, 2025
For decades, the United States has shouldered a disproportionate share of global pharmaceutical costs, accounting for 70% of global biopharma profits and over 80% of new drug launches. While this has helped drive significant medical innovation and supported the majority of global drug launches, it has also resulted in higher out-of-pocket costs for American patients.
